What Is a Clinical Events Committee?

A Clinical Events Committee (CEC) is an independent panel of clinical experts that adjudicates adverse events, neurological status, protocol deviations, and other critical endpoints in clinical trials. Its purpose is to ensure consistent, objective assessment of trial data and help minimize investigator bias or sponsor influence.

Why This Matters for Device Sponsors:

• FDA reviewers scrutinize CEC independence and methodology

• Poor CEC design can trigger formal rejection letters

• The right CEC structure accelerates approval timelines

• Independent oversight reduces regulatory risk

The Evidence: Independent CECs Are Important

BSC®'s landmark research, Mitigating Adverse Event Reporting Bias in Spine Surgery, published in The Journal of Bone & Joint Surgery, revealed systematic patterns in adverse event reporting that every device sponsor must understand.

Key Findings:

• Independent reviewers reclassified 37% of adverse events originally categorized by study investigators

• 92% of reclassifications involved upgrading severity or device-relatedness

• Industry-sponsored studies are 3.6 times more likely to report positive outcomes than independent research

This research, led by BSC®'s Chief Scientific Officer, Greg Maislin, represents the first quantitative analysis of investigator bias in medical device trials.

FDA Regulatory Evolution: What Sponsors Must Know

The FDA continues to evolve its thinking on CECs, with greater emphasis on CEC credibility and independence. We have seen formal rejection letters stating reviewers "do not believe your CEC," heightened scrutiny following controversies in orthopedics and spine, demands for transparency in adjudication processes, and requirements for statistical oversight to detect reporting bias.

The New Reality: Simply having a CEC is no longer enough. It's about having the "right" committee and process.

The Independence Challenge

Many sponsors outsource CECs to full-service CROs. This can create efficiency gains, but not all CROs are created equal. CECs cannot compensate for a lack of consistent and ongoing site monitoring. A truly independent CEC should include clinicians with no financial relationship to the sponsor, clinicians with no financial relationship to the full-service CRO, and a pre-specified and transparent adjudication process.

CEC Framework: Designed for FDA Success

Our 35+ years of FDA experience have taught us that successful CECs require:

Therapeutic Expertise Without Conflicts — Adjudicators familiar with your device, no financial relationships that could compromise objectivity, and specialized knowledge of regulatory clinical trials.

Pre-Specified Adjudication Process — Event categories defined upfront, clear algorithms for classification decisions, and documentation aligned with FDA expectations.

Transparency and Documentation — Auditable processes that can withstand FDA scrutiny, comprehensive reporting for regulatory submissions, and independent statistical oversight when requested.

Strategic Implications for Device Sponsors

Early CEC decisions can define your trial's regulatory fate. FDA rejection doesn't just delay timelines — it can compromise fundraising and investor confidence, partnership negotiations, commercial positioning and market entry, and competitive advantage.

Key Principles for Success:

1. Start Early — Design the CEC structure during protocol development, pre-specify adjudication process before first patient enrollment, and ensure independence from trial management.

2. Choose Expertise Over Convenience — Just because they are recommended by your CRO does not mean they are appropriate for your trial. Therapeutic expertise must be conflict-free.

3. Plan for FDA Scrutiny — Document every decision and rationale, maintain auditable processes, and prepare for detailed reviewer questions.

About BSC®

Our track record speaks for itself: 35+ years of successful FDA submissions, hundreds of studies across medical device categories, published research on CEC best practices, and long-standing FDA relationships and panel meeting experience.

We do not provide complete CEC services. We are happy to connect you with strategic partners who do. We offer independent statistical consultation of CEC proposals and provide CEC statistical advisory services to ongoing CECs.

[1] Auerbach JD, McGowan KB, Halevi M, et al. Mitigating Adverse Event Reporting Bias in Spine Surgery. The Journal of Bone & Joint Surgery 95(16):1450-1456, August 21, 2013. DOI: 10.2106/JBJS.L.00251